bioMerieux’s Q2 performance was supported by resilient growth across both segments with the routine testing business witnessing healthy momentum. However, higher sales & marketing expenses weighed on profitability. Meanwhile, management reiterated its 2023 guidance. Overall, with promising testing market dynamics along with an encouraging start for its new product launches and anticipated approvals, our positive recommendation is reiterated.
